← 返回

用适配器 CAR-T 细胞联合靶向可溶性潜伏型 TGF-β 与实体瘤相关抗原

英文原题:Combined targeting of soluble latent TGF-ß and a solid tumor-associated antigen with adapter CAR T cells.

查看英文原题

Combined targeting of soluble latent TGF-ß and a solid tumor-associated antigen with adapter CAR T cells.

PubMed 2022/11/11(内容时间) Oncoimmunology Q1 · IF 6.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

实体瘤由恶性细胞和非恶性细胞组成,它们共同构建了局部肿瘤微环境(TME)。此外,TME的特征在于表达众多可溶性因子,如TGF-。TGF-通过抑制T细胞效应功能和促进肿瘤侵袭性,在TME中发挥重要作用。迄今为止,CAR-T 细胞仅靶向位于细胞膜上的肿瘤相关抗原(TAA)。因此,需要利用可溶性抗原作为TME内CAR靶点的策略。本研究展示了一种新方法,使用Adapter CAR(AdCAR)T细胞检测胰腺肿瘤模型TME中的可溶性潜伏TGF-。我们表明,AdCAR与相应适配器结合可用于在体外和体内感知可溶性肿瘤来源的潜伏TGF-。感知可溶性抗原诱导AdCAR T细胞的细胞活化和效应细胞因子产生。此外,我们评估了AdCAR T细胞在体内通过靶向CD66c作为TAA,联合靶向可溶性潜伏TGF-和肿瘤细胞杀伤。总之,我们的研究通过可溶性潜伏TGF-拓宽了AdCAR T细胞的可靶向部分谱。

展开英文摘要原文

Solid tumors consist of malignant and nonmalignant cells that together create the local tumor microenvironment (TME).

Additionally, the TME is characterized by the expression of numerous soluble factors such as TGF- . TGF- plays an important role in the TME by suppressing T cell effector function and promoting tumor invasiveness. Up to now CAR T cells exclusively target tumor-associated antigens (TAA) located on the cell membrane.

Thus, strategies to exploit soluble antigens as CAR targets within the TME are needed.

This study demonstrates a novel approach using Adapter CAR (AdCAR) T cells for the detection of soluble latent TGF- within the TME of a pancreatic tumor model.

We show that AdCARs in combination with the respective adapter can be used to sense soluble tumor-derived latent TGF- , both in vitro and in vivo . Sensing of the soluble antigen induced cellular activation and effector cytokine production in AdCAR T cells.

Moreover, we evaluated AdCAR T cells for the combined targeting of soluble latent TGF- and tumor cell killing by targeting CD66c as TAA in vivo . In sum, our study broadens the spectrum of targetable moieties for AdCAR T cells by soluble latent TGF- .

论文信息

作者
Werchau N、Kotter B、Criado-Moronati E、Gosselink A、Cordes N、Lock D、Lennartz S、Kolbe C
单位
Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.Germany
期刊
Oncoimmunology2022
原文标识
PubMed 36387056 · DOI 10.1080/2162402X.2022.2140534